GPS Stock Recent News

SAN JOSE, Calif.--(BUSINESS WIRE)--As the energy needs of data centers continue to significantly outpace supply, a new report from Bloom Energy (NYSE: BE), a global leader in power solutions, predicts that 35 GW of data center capacity will be announced within the next five years — equivalent to over six times the average energy capacity used by New York City annually. To meet the soaring demand, data centers are adopting onsite power systems as a primary energy source, a shift that reflects th.

GAP's brand strength, digital innovation and growth initiatives make it a top pick in retail. Strong fundamentals and undervaluation offer great investment potential.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

ANF and GAP have competed neck to neck for quite some time now. Let us find out which of these industry giants will capture the favor of investors in 2025.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Moody's and S&P Global dominate the credit rating market, each with a 40% share, playing a key role in the world's economy. Moody's higher exposure to the high-quality credit ratings business justifies a higher valuation, but the size of the premium is somewhat questionable. Debt issuance had an extraordinary recovery in 2024, but the size of the slowdown expected in 2025 remains a big uncertainty.

Note: Gap's FY'23 ended on February 3, 2024.

- GPS Currently Investigated in Phase 3 REGAL Trial in Adult AML Patients – Interim Analysis Anticipated in Q4 2024 - - RPDD Provides Eligibility for GPS to Receive a Priority Review Voucher (PRV) Upon Marketing Approval that can be Transferred/Sold to Other Parties – - Recent Valuations for PRVs Remain Attractive (~$100 million/each) – NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to Galinpepimut-S (GPS), an immunotherapeutic targeting Wilms Tumor-1 (WT1), for the treatment of pediatric acute myeloid leukemia (AML). “GPS has already demonstrated promise in clinical settings for AML, and we believe its potential could extend to pediatric patients,?

WARREN, N.J., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, plans to update shareholders on multi-billion dollar asset valuation following this week's $1b+ revenue potential announcement.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.